Ambien CR
This non-benzodiazepine hypnotic is delivered in 2 stages through the use of a bi-layered tablet.
SANOFI-AVENTIS
Extended-release hypnotic approved for improving sleep onset and maintenance
This non-benzodiazepine hypnotic is delivered in 2 stages through the use of a bi-layered tablet. The first layer dissolves quickly to induce sleep, while the second layer is released more gradually to improve sleep maintenance. Extended-release zolpidem was approved on September 2, 2005, for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Safety. Like other sedative/hypnotic drugs, extended-release zolpidem has CNS-depressant effects. Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effects of extended-release zolpidem. An additive effect on psychomotor performance between alcohol and zolpidem has been demonstrated. Due to its rapid onset of action, extended-release zolpidem should only be ingested immediately prior to going to bed. Patients should be cautioned against engaging in hazardous activities requiring complete mental alertness or motor coordination after ingesting the drug. Sedative/hypnotic drugs should be administered with caution to patients exhibiting signs or symptoms of depression. Zolpidem is classified as a Schedule IV controlled substance under the Controlled Substances Act. Patients with a history of addiction to, or abuse of, drugs or alcohol should be monitored carefully when receiving extended-release zolpidem since these individuals are at an increased risk for misuse and abuse of the drug and addiction to the drug. The most commonly reported adverse events associated with extended-release zolpidem are headache, somnolence, and dizziness.
Dosing. The recommended dose of extended-release zolpidem for non-elderly adults is 12.5 mg immediately before bedtime. The recommended dose of extended-release zolpidem for elderly (aged ≥65 y) or debilitated patients or patients with hepatic insufficiency is 6.25 mg immediately before bedtime. Zolpidem extended-release tablets should be swallowed whole, not divided, chewed, or crushed.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
